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RESEARCH ARTICLE

Reducing Overutilization of Testing for
Clostridium difﬁcile Infection in a Pediatric
Hospital System: A Quality Improvement Initiative
J. Michael Klatte, MD,a Rangaraj Selvarangan, BVSc, PhD, D(ABMM),b Mary Anne Jackson, MD,b Angela L. Myers, MD, MPHb

ABSTRACT

OBJECTIVES: Study objectives included addressing overuse of Clostridium difﬁcile laboratory
testing by decreasing submission rates of nondiarrheal stool specimens and specimens from
children #12 months of age and determining resultant patient and laboratory cost savings associated
with decreased testing.

METHODS: A multifaceted initiative was developed, and components included multiple provider
education methods, computerized order entry modiﬁcations, and automatic declination from
laboratory on testing stool specimens of nondiarrheal consistency and from children #12 months
old. A run chart, demonstrating numbers of nondiarrheal plus infant stool specimens submitted
over time, was developed to analyze the initiative’s impact on clinicians’ test-ordering practices. A
p-chart was generated to evaluate the percentage of these submitted specimens tested biweekly over
a 12-month period. Cost savings for patients and the laboratory were assessed at the study period’s
conclusion.
RESULTS: Run chart analysis revealed an initial shift after the interventions, suggesting a
temporary decrease in testing submission; however, no sustained differences in numbers of
specimens submitted biweekly were observed over time. On the p-chart, the mean percentage of
specimens tested before the intervention was 100%. After the intervention, the average percentage
of specimens tested dropped to 53.8%. Resultant laboratory cost savings totaled nearly $3600, and
patient savings on testing charges were ∼$32 000.
CONCLUSIONS: Automatic laboratory declination of nondiarrheal stools submitted for CDI
testing resulted in a sustained decrease in the number of specimens tested, resulting in signiﬁcant
laboratory and patient cost savings. Despite multiple educational efforts, no sustained changes in
physician ordering practices were observed.
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The diagnosis of pediatric Clostridium
difﬁcile infection (CDI) has increased over
the past 10 to 20 years and has been
associated with increased health care
costs.1–3 Despite a recent American Academy
of Pediatrics policy statement outlining
appropriate indications for pediatric CDI
testing, a signiﬁcant number of institutions
have few restrictions on testing.4,5 The
American Academy of Pediatrics and
Infectious Diseases Society of America
guidelines recommend against CDI testing
of nondiarrheal stool (formed or soft stool
consistency, per visual inspection)
specimens.4,6
This recommendation is based in part on
the statistical principle of a positive test
result (in this situation, a positive test result
for CDI) demonstrating poor predictive
utility in the presence of a low pretest
probability.7 For diagnosis of pediatric CDI,
low prevalence rates of disease in children,
when combined with the known
sensitivities and speciﬁcities of testing
methods such as stool enzyme
immunoassay, lead to a poor positive
predictive value for this testing method.4
Newer testing techniques, such as nucleic
acid–based polymerase chain reaction
(PCR) analysis for C. difﬁcile strains that
harbor toxin-producing genes, are highly
sensitive and speciﬁc yet are plagued by
the inability to differentiate asymptomatic
colonization from symptomatic CDI.8,9 For
the pediatric population, in whom rates of
asymptomatic C. difﬁcile colonization
(particularly in infants #12 months of
age) can be elevated4 and in whom
gastroenteritis caused by etiologies other
than C. difﬁcile (eg, adenoviruses,
noroviruses, and rotaviruses10) is
exceedingly more common, close adherence
to published recommendations for
appropriate testing is therefore extremely
important.
Before development of this quality
improvement (QI) initiative, the Children’s
Mercy Hospital (CMH) microbiology
laboratory began recording the consistency
of stool specimens submitted for CDI
testing in November 2010. This study was
initiated after microbiology laboratory
personnel data review revealed that
10

nondiarrheal stools (soft or formed) were
frequently being submitted for CDI
testing. In this study, we sought to work
closely with the microbiology laboratory
to develop, implement, and evaluate the
impact of a multifaceted QI initiative,
designed to reduce overuse of pediatric CDI
testing at CMH. Reduction of testing
overuse was facilitated by accomplishment
of our primary aim: reducing rates of
nondiarrheal specimens and those from
infants #12 months old both submitted and
tested for CDI (from both inpatients and
outpatients, although baseline data review
revealed that a majority of specimens
were submitted from inpatients). Our
secondary aim included calculation of cost
savings resulting from the intervention.
Before the implementation of the initiative,
there was no routine process to notify
the ordering physician that a nondiarrheal
stool had been submitted for testing,
and the study aimed to address this
problem as well.

METHODS
Study Design
The CMH system, located in Kansas City,
Missouri, includes a 302-bed tertiary
hospital, a 53-bed satellite facility, and
outpatient primary and subspecialty clinics.
The system’s main hospital campus
serves as the primary training site for
72 categorical pediatrics resident
physicians and 24 combined internal
medicine and pediatrics residents. The
multidisciplinary team included members
of the Infectious Diseases Division, the
microbiology laboratory director, the
director of the Gastroenterology Division,
members of the Quality and Safety
Department, and the CMH Medical
Informatics Committee. Laboratory testing
for CDI at CMH throughout the study
period entailed testing stool specimens for
the presence of both glutamate
dehydrogenase (GDH) antigen (Ag), an
enzyme produced by both toxigenic and
nontoxigenic strains of C. difﬁcile, and
C. difﬁcile toxin antigen (toxin Ag). Reﬂex
PCR testing for C. difﬁcile toxin–producing
gene was performed on specimens
testing positive for GDH Ag but negative for
toxin Ag, to optimize testing sensitivity.8

Planning the Intervention
Multiple formative discussions were held
between the microbiology laboratory
director and members of the Infectious
Diseases Division. Active input was
subsequently sought from the director of
the Gastroenterology Division, after analysis
of preexisting laboratory data, which
revealed that a majority of specimens
submitted for CDI testing were directly
ordered either by gastroenterology or by
hospital medicine physicians at the behest
of consulting gastroenterology physicians.
Review of the existing literature on
indications for pediatric CDI testing and
additional collaboration between the
aforementioned parties resulted in
development of the intervention’s
educational components and the proposed
plan for modiﬁcation of computerized order
entry for CDI and automatic laboratory
declination of nondiarrheal stool specimens
submitted for testing.
Multidisciplinary team attendance at
monthly meetings of the CMH Quality and
Safety Department, as well as the CMH
Medical Informatics Committee, allowed
widespread dissemination of educational
materials and formulation of computerized
order entry changes according to team
speciﬁcations.
Tested nondiarrheal stool specimens
obtained from patients .12 months old, in
whom concern existed for toxic megacolon
or severe ileus, were not included in the
study analysis (as per review of medical
record documentation before the
intervention, n 5 2, and as indicated by
computerized order entry documentation
after the intervention, n 5 2). All other
specimens tested during the study that
were either nondiarrheal in consistency or
from patients #12 months old were also
stratiﬁed by testing result (positive or
negative). After the intervention, ordering
clinicians could choose to override the
automatic declination by contacting the
clinical microbiology laboratory within
24 hours of test declination. In certain
circumstances as deemed necessary by
laboratory personnel, subsequent clinical
microbiology discussion with the Infectious
Diseases Division (regarding the
KLATTE et al

appropriateness of testing) occurred before
an order of automatic declination could be
overridden.

Intervention
The initiative involved development and
simultaneous implementation of several
intervention components. Educational
facets included teaching pediatric
residents through a didactic lecture,
because review of baseline data revealed
that ∼30% of all nondiarrheal specimens
testing positive for CDI were ordered by
resident physicians. Education of CMHafﬁliated providers was facilitated by
publication of an article in a monthly
hospital-based newsletter that outlined
clinical features, risk factors, and
appropriate diagnosis and treatment of
CDI. Most importantly, an evidencebased algorithm was developed to
optimize CDI test ordering. The
algorithm was made available on
the hospital’s clinical practice guidelines
Web site (https://www.childrensmercy.
org/Health_Care_Professionals/
Medical_Resources/Clinical_Practice_
Guidelines/Clostridium_Difﬁcile/
Clostridium_Difﬁcile/).
The second component involved development
of computerized order entry modiﬁcations for
CDI testing, including mandatory completion
of 2 additional ﬁelds before submission that
included whether the patient age was
#12 months and whether the clinician
suspected toxic megacolon or the patient had
evidence of severe ileus. The requirement of
having the ordering clinician enter the
patient’s age as part of the order entry
process was instituted to facilitate automatic
laboratory declination of specimens
submitted from patients #12 months old,
given the increased prevalence of
asymptomatic C. difﬁcile colonization in this
age group.4 Because the clinician was
prompted to indicate whether toxic
megacolon or severe ileus was suspected, the
laboratory was notiﬁed that a submitted
specimen needed to be tested, even if it was
of a nonliquid consistency (because toxic
megacolon and severe ileus, which occur in
,2% of children with CDI, are the only clinical
scenarios for which testing of nonliquid
specimens should be performed).1,6

Finally, automatic laboratory declination
was implemented for nondiarrheal stools
submitted for testing, unless severe ileus
was present or toxic megacolon was
suspected. Automatic declination was
communicated to submitting providers by
laboratory posting of a comment in the
patient’s electronic medical record, which
stated, “Test not performed. Non-liquid stool
is not acceptable for testing. Notify lab
within 24 hours if testing is clinically
warranted.”
The evidence-based algorithm,
computerized order entry modiﬁcations,
and automatic laboratory declination of
nondiarrheal stool submissions were all
implemented on April 15, 2013. The
educational lecture and the newsletter
article occurred on April 10, 2013 and upon
publication of the March/April newsletter
issue, respectively.
Submitted specimens were stratiﬁed
according to patient age at the time of
specimen submission (ie, #12 months vs
.12 months). Specimens submitted from
infants #12 months of age were
automatically declined throughout the study
period, unless the ordering clinician
contacted the clinical microbiology
laboratory.

(relative to those submitted for testing)
during the study period.
Laboratory cost savings were calculated
from costs incurred for both materials and
labor needed to perform testing in 2013.
GDH Ag plus toxin Ag cost per test was
$12.46, whereas the cost of performing 1
C. difﬁcile toxin gene PCR test at the
reference laboratory was $45.00 per test.
Cost of PCR testing was not included in the
analysis, because this reﬂex step was
avoided by automatic nondiarrheal stool
testing declination after the intervention.
Laboratory technician time cost was
determined to be $4.00 per test, based on
time needed to perform 1 test (estimated
to be 10 minutes).
Patient savings on testing charges were
calculated from unadjusted (ie, before
insurance authorization) 2013 CMH charge
data and included a GDH Ag plus toxin Ag
charge of $147.00 per test. Toxin gene PCR
charges (not included in the analysis) were
$137.00 per test.

Data were collected and recorded in 2-week
time periods over a 12-month duration
(October 15, 2012 to October 15, 2013) and
included specimen numbers submitted for
testing and numbers of specimens actually
tested.

RESULTS
During the baseline period of the study
(October 15, 2012–April 14, 2013),
534 specimens were submitted, including 21
(4%) from children #12 months old. Of the
513 specimens obtained from children
.12 months old, 318 (62%) were
nondiarrheal. A total of 47 out of 318 (15%)
tested positive (ie, either GDH Ag positivity
plus toxin Ag positivity or GDH Ag
positivity with toxin Ag negativity, plus a
positive toxin gene PCR test result). Of
21 specimens submitted from children
#12 months old, 16 (76%) were tested, with
1 specimen yielding a positive result. With
respect to antibiotic therapy receipt, 94%
(45 out of 48; 47 nondiarrheal positives plus
1 positive test from a child #12 months
old) of patients received antibiotic therapy
directed against CDI after return of positive
testing results.

By using QI Macros for Excel software
(Microsoft Corporation, Redmond, WA), we
created a run chart to track the number of
specimens submitted on a biweekly basis
over the study period. A p-chart was also
generated, to demonstrate the percentage
of tests performed on a biweekly basis

During the postintervention period (April 15,
2013–October 15, 2013), 485 specimens
were submitted, including 11 (2%) from
those #12 months old and 474 from
children .12 months old (Fig 1). A total of
257 out of 474 (54%) tests were performed
on specimens obtained from children

Project Measures
This study’s primary process measure was
the percentage of stool specimens
submitted for CDI testing over time that
were either nondiarrheal or from children
#12 months old, while the primary outcome
measure was the number of these stool
specimens tested for C. difﬁcile.

Data Collection
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FIGURE 1 Specimens submitted, tested, and rejected during the postintervention period. aAfter ordering clinician discussion with the laboratory.
b
Patient treated with antibiotic therapy for CDI after return of positive test result. c12 of 15 patients treated with antibiotic therapy for
CDI after return of positive test result.

.12 months old, after automatic laboratory
declination of nondiarrheal stool specimens
(n 5 217; 46%). Of the 257 specimens
tested, 62 (24%) were determined to be
inappropriate but were tested after
ordering clinician discussion with the
laboratory. Fifteen (24%) of 62 specimens
tested positive. Of the 11 specimens
submitted from individuals #12 months old,
4 (36%) were tested after clinician
discussion with the laboratory, and 1 (9%)
specimen tested positive. With respect to
antibiotic therapy, 81% (13 out of 16;
15 nondiarrheal positives plus 1 positive
test from a child #12 months old) of
patients received antibiotic therapy directed
against CDI after return of positive testing
results.
From the date of implementation of the
intervention’s major components on April
15, 2013 through completion of week 42 of
the study period on August 4, 2013, an initial
shift, reﬂecting a decrease in the numbers
of specimens submitted on a biweekly
basis over time, was detected via run chart
analysis. However, subsequent data
collected pertaining to nondiarrheal and
infant stool specimen submission failed to
show a continued shift (Fig 2).
The percentage of tests performed on a
biweekly basis (relative to the total
numbers of specimens submitted for
testing) declined sharply after the
intervention (Fig 3).
12

Between October 15, 2012 and April 14, 2013,
a total of 334 tests (318 nondiarrheal
specimens and 16 specimens from children
#12 months old) accounted for
$5497.64 in laboratory costs. Corresponding
unadjusted patient charges for these tests
totaled $49 098.00. From April 15, 2013 to
October 15, 2013, a total of 66 tests
(performed on 62 nondiarrheal specimens
and 4 specimens from children #12 months
old) accounted for $1086.36 in laboratory
costs, with corresponding unadjusted
patient charges of $9702.00.
The 217 nondiarrheal specimens
automatically declined by the laboratory
after the intervention represent laboratory
cost savings of $3571.82 and unadjusted
patient charge savings totaling $31 899.

DISCUSSION
Diagnostic guidelines to optimize
identiﬁcation of those with CDI speciﬁcally
recommend against testing nondiarrheal
stools in the absence of toxic megacolon
and from infants ,12 months of age.4,6 Yet
this is a common practice that results in
excessive expense and potential exposure to
unnecessary antibiotics. For instance,
1 previous study evaluating optimization of
CDI testing in adults found that 39% of all
CDI testing at the study institution could
have been avoided if clinicians had only
submitted specimens from patients with
both diarrhea and a history of antibiotic

use.11 After our intervention, we observed a
45% decrease in the number of specimens
tested (217 out of 485 submitted
nondiarrheal stool specimens automatically
declined by the laboratory and subsequently
not tested). Development of an initiative that
eliminated testing of nondiarrheal stool
specimens resulted in a substantial decline
in inappropriate CDI testing, accounting for
.$35 000 in overall savings, thus
demonstrating a clear ﬁnancial beneﬁt to
optimizing CDI testing. Additionally,
laboratory testing costs and patient charge
savings are probably underestimated,
because automatic declination negated the
need for any potential reﬂex PCR testing in
the postintervention period.
This study is limited by the fact that we did
not correlate the number of inpatient
tests ordered to the inpatient census at
the time of testing, which impeded our
ability to determine whether the rate of
inpatient test ordering changed over time.
However, our average patient census was
fairly stable throughout the study period
and thus is unlikely to have introduced
much bias.
Although it appears that there may have
been an initial decrease in the frequency of
nondiarrheal stool specimens submitted for
testing in the postintervention period, a
sustained decline in submission of such
specimens was not conﬁrmed over time.
This observation suggests the need for
KLATTE et al

FIGURE 2 Run chart showing the number of specimens submitted during the study period. The x-axis is in 2-week increments. Number
1 represents October 15 to 28, 2012, and number 26 represents September 30 through October 15, 2013. The y-axis is the number of
specimens submitted. The vertical line represents intervention implementation.

provision of additional and ongoing
feedback and education, rooted in evidencebased practice, and targeted toward the
specialties and individual clinicians
continuing to consistently demonstrate
inappropriate ordering tendencies.
Among the most common reasons given by
clinicians for overriding an automatic
laboratory declination was that the
patient being tested had a concurrent
diagnosis oﬁnﬂammatory bowel
disease and therefore was more likely to
have symptomatic CDI, regardless of
the submitted stool specimen consistency.
Although the diagnosis of inﬂammatory
bowel disease in and of itself has been
shown to be a risk factor for development
of CDI, rates of colonization with
toxigenic strains of C. difﬁcile in this
pediatric patient subpopulation may be
up to 14% greater than in otherwise
healthy children; therefore, application of

judicious testing according to published
guidelines also applies to this patient
population.12,13
Another common indication given by
clinicians for overriding an automatic
laboratory testing declination was that “it
[the stool specimen] was liquid, but it had
to be scraped out of a diaper . . . so that’s
why it appears to be non-liquid.” Additional
measures to reduce these types of
inappropriate specimen submissions might
also include timely nursing-to-ordering
provider notiﬁcation, in the event that a
diarrheal stool specimen cannot be
obtained for CDI testing.
Still other measures that could be
undertaken to reduce submission of
nondiarrheal specimens could include
instructing ordering clinicians to advise
parents of pediatric outpatients that if
stools subsequently develop a formed

consistency, then specimen submission for
CDI testing is longer indicated.

CONCLUSIONS
Our study highlights the need for judicious
pediatric CDI testing and thus treatment
according to published guidelines and
standards.4,6 Reducing overuse of CDI testing
has the potential to improve patient care by
reducing unnecessary antibiotic exposure
in patients with a positive test who do not
have symptoms consistent with CDI.
Furthermore, this is a good example of
ﬁnancial stewardship in this era in which
reduction of unnecessary costs and patient
charges are becoming increasingly
important. Finally, this study also
underscores the importance of active,
ongoing collaboration between physicians
and microbiology laboratory professionals
and the necessity of this partnership for
timely institution of hospital policies
pertaining to infectious diseases.

FIGURE 3 P-chart showing the percentage of tests performed (relative to those submitted for testing) in 2-week increments during the study
period. Number 1 represents October 15 to 28, 2012, and number 26 represents September 30 through October 15, 2013. The y-axis is the
percentage of tests performed. LCL, lower control limit; UCL, upper control limit.
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Development of a hospital-speciﬁc, best
practice model for appropriate CDI diagnosis
and testing is a primary step toward
development of a CDI stewardship initiative.14
Several core components of this initiative,
including automatic laboratory declination
of nondiarrheal stool specimens submitted
for testing, computerized order entry
modiﬁcations, and access to the evidencebased algorithm, have remained in place
after the conclusion of this study. A recent
increase in clinicians’ requesting of testing
on automatically rejected specimens has
been observed, and the multidisciplinary
team is planning additional interventions to
address this issue.
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